MONTREAL – April 22nd, 2021 – Soundbite announces the company has received Food and Drug Administration (FDA) 510(k) clearance for the SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire...
MONTREAL – February 9th, 2021 – Soundbite announces Health Canada Approval for SoundBite Crossing System ‐ Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SCS-P (14P) is intended for the treatment...
MONTREAL – Jan 26th, 2021 – Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical...
MONTREAL, June 17, 2020 – SoundBite Medical Solutions Inc. (SBMS) today announced that it was granted by Engineers Canada, the national organization of the 12 provincial and territorial associations that regulate the...
MONTREAL - February 3, 2020 – SoundBite Medical Solutions Inc. (SBMS) announced today that it has received FDA IDE (Investigational Device Exemption) approval to start the ACTIVE Clinical Study with the SoundBite™...
